Research programme: amyotrophic lateral sclerosis therapeutics - Eli Lilly/Project ALS
Latest Information Update: 21 Nov 2013
Price : $50
At a glance
- Originator Eli Lilly; Project A.L.S.
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 19 Nov 2013 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)